Literature DB >> 6448038

Screening of antiserotoninergic drugs with the genetically dystrophic chicken.

M S Hudecki, C M Pollina, A K Bhargava, R S Hudecki.   

Abstract

Line 413 early-onset, genetically homozygous dystrophic chickens were given twice-daily intraperitoneal injections of the antiserotoninergic drugs p-chlorophenylalanine hydrochloride, fluoxetine hydrochloride, ergonovine maleate, nortriptyline hydrochloride, methiothepin maleate, and methysergide bimaleate in combination with penicillamine. Except in one case, treatment with drugs significantly prolonged the righting ability of the treated dystrophic chickens, as measured by a periodic standardized flip-test procedure. Abnormally high levels of plasma creatine phosphokinase, lactate dehydrogenase, and SGOT were found in the untreated dystrophic chickens. However, of the drug-treated dystrophic chickens, in some cases the plasma enzyme activities were reduced whereas in others they were enhanced. In agreement with previous findings, the blood serotonin levels of the dystrophic chickens were found at all age groups to be significantly higher than those in the corresponding normal chickens. This phenomenon may in part account for the improvement in righting ability demonstrated in the dystrophic chickens receiving treatment with antiserotoninergic drugs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6448038     DOI: 10.1001/archneur.1980.00500580041005

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  2 in total

1.  Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.

Authors:  Trent A Waugh; Eric Horstick; Junguk Hur; Samuel W Jackson; Ann E Davidson; Xingli Li; James J Dowling
Journal:  Hum Mol Genet       Date:  2014-04-23       Impact factor: 6.150

2.  In vivo effects of protease inhibitors on chickens with hereditary muscular dystrophy.

Authors:  M S Hudecki; C M Pollina; R R Heffner
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.